Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Portage Biotech Inc | PRTG | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 0.2502 | 04:17:26 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.2502 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.1999 - 4.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.2502 | USD |
Portage Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 4.95M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Portage Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PRTG Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.22 | 0.35 | 0.22 | 0.2694201 | 246,118 | 0.0302 | 13.73% |
| 1 Month | 0.571 | 0.64 | 0.1999 | 0.3175527 | 152,102 | -0.3208 | -56.18% |
| 3 Months | 0.8685 | 0.8685 | 0.1999 | 0.4438927 | 101,483 | -0.6183 | -71.19% |
| 6 Months | 2.07 | 2.17 | 0.1999 | 0.6930957 | 66,544 | -1.82 | -87.91% |
| 1 Year | 3.59 | 4.40 | 0.1999 | 1.17 | 42,725 | -3.34 | -93.03% |
| 3 Years | 28.15 | 44.9763 | 0.1999 | 8.57 | 36,264 | -27.90 | -99.11% |
| 5 Years | 37.50 | 44.9763 | 0.1999 | 8.96 | 35,015 | -37.25 | -99.33% |
Portage Biotech Description
| Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others. |
